Herceptin Biosimilar Market, by Indication (Breast Cancer, Gastric Cancer, and Others), by Distribution Channel (Hospital, Oncology Centers, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	175 Pages	Coherent Market Insights	May, 2022	CMI17212669

Best Price Guarantee
Price	from $4,500
Length	175 Pages
Publisher	Coherent Market Insights
Published Date	May, 2022
SKU	CMI17212669

Herceptin Biosimilar Market, by Indication (Breast Cancer, Gastric Cancer, and Others), by Distribution Channel (Hospital, Oncology Centers, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used for the treatment of breast cancer and gastric cancer. Herceptin is mainly used to treat patients suffering from cancer and diagnosed with HER2 receptor positive. Herceptin mechanism of action is binding itself to HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals and thus decreasing the mutation of cells. Herceptin acts as an immune targeted therapy for breast cancer patients.
Market Dynamics
Product approvals and launches are the factors driving the growth of the global herceptin biosimilar market. For instance, in February 2020, Pfizer Inc., a biotechnology and pharmaceutical company in the U.S., launched the trastuzumab biosimilar, Trazimera, for treatment of human epidermal growth receptor causing breast cancer and metastatic gastric cancer.
Key features of the study:
This report provides in-depth analysis of the global herceptin biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Herceptin biosimilar market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global herceptin biosimilar market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herceptin biosimilar market.
Detailed Segmentation:
Global Herceptin Biosimilar Market, By Indication:
Breast Cancer
Gastric Cancer
Others
Global Herceptin Biosimilar Market, By Distribution Channel :
Hospitals
Oncology Centers
Others
Global Herceptin Biosimilar Market, By Region:
North America
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country:
U.S.
Canada
Latin America
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Amgen Inc. *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
AryoGen Biopharma
Biocon Limited
Celltrion Inc.
Pfizer Inc.
Merck & Co., Inc.
Accord Healthcare Ltd.
Gedeon Richter Plc.
Genor Biopharma Company Ltd
Mabion SA
Mylan N.V.
Roche Holding AG
Samsungbioepis Co,.Ltd

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Indication; Market Snippet, By Distribution Channel; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Impact Analysis; Market Opportunities; Regulatory Scenario; Recent Product Approval/ Launch; Key Development; PEST Analysis; Epidemiology; Mergers and Acquisitions; Value Chain Analysis
4. Global Herceptin Biosimilar Market, Impact of COVID-19 Pandemic: Post COVID-19 Impact; Demand and Supply Chain Analysis; Government Initiative
5. Global Herceptin Biosimilar Market, By Indication, 2017 - 2028 (US$ Mn): Introduction; Market Share Analysis, 2022 and 2028 (%); Y-o-Y Growth Analysis, 2017 - 2028; Segment Trends; Breast Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn); Gastric Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
6. Global Herceptin Biosimilar Market, By Distribution Channel, 2017 - 2028 (US$ Mn): Introduction; Market Share Analysis, 2022 and 2028 (%); Y-o-Y Growth Analysis, 2017 - 2028; Segment Trends; Hospitals; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn); Oncology Centers; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
7. Global Herceptin Biosimilar Market, By Region, 2017 - 2028 (US$ Mn): Introduction; Market Share Analysis, By Region, 2022 and 2028 (%); Y-o-Y Growth Analysis, For Countries, 2017 - 2028; North America; Introduction; Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn); Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn); Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn); Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn); Germany; U.K.; France; Italy; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn); Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn); China; India; Japan; Australia; South Korea; ASEAN; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn); Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn); Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn); South Africa; Central Africa; North Africa
8. Competitive Landscape: Company Profiles; Amgen Inc.; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; AryoGen Biopharma; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Biocon Limited; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Celltrion Inc.; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Pfizer Inc.; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Merck & Co., Inc.; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Accord Healthcare Ltd.; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Gedeon Richter Plc.; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Genor Biopharma Company Ltd; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Mabion SA; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Mylan N.V.; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Market Strategies; Roche Holding AG; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Market Strategies; Samsungbioepis Co,.Ltd; Company Overview; Clinical Trial Phase Portfolio; Financial Overview; Key Highlights; Market Strategies; Market Strategies; *Browse 33 market data tables and 32 figures on "Herceptin Biosimilar Market– Global forecast to 2028”.

Global Paclitaxel Injection Market, By Cancer Type (Breast Cancer, Gastric Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Kaposi sarcoma, Others), By Distribution Channel (Online Pharmacies , Retail Pharmacies , Hospital Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

March, 2024 | Published by: Coherent Market Insights | USD $4,500
Interventional Oncology Ablation Market, By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation ), By Indication (Liver Cancer, Kidney Cancer, Lung Cancer, Others), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

October, 2023 | Published by: Coherent Market Insights | USD $4,500
Immuno-Oncology Assays Market, By Product (Consumables and Software), By Technology (Immunoassay, PCR, NGS, Fow Cytometry, and Others), By Indication (Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, and Others), By Application (Clinical Diagnostics and Research and Development), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

May, 2024 | Published by: Coherent Market Insights | USD $4,500
Breast Imaging Market, By Technology (Ionizing Breast Imaging, Non-ionizing Breast Imaging, and Others), By End User (Hospitals, Diagnostic Centers, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

May, 2024 | Published by: Coherent Market Insights | USD $4,500
PARP Inhibitor Market, By Drug Type (Niraparib, Olaparib, Rucaparib, Talazoparib, Veliparib, Others), By Application (Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

July, 2024 | Published by: Coherent Market Insights | USD $4,500
Immuno-Oncology Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Cytokines), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End-Users - Global Forecast 2024-2030

January, 2024 | Published by: 360iResearch | USD $4,749

PDF E-mail From Publisher:	$4,500
Site License Fulfilled by Publisher:	$7,000
Global Site License Fulfilled by Publisher:	$10,000

Herceptin Biosimilar Market, by Indication (Breast Cancer, Gastric Cancer, and Others), by Distribution Channel (Hospital, Oncology Centers, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Sh

Research Assistance

Other tasks

Herceptin Biosimilar Market, by Indication (Breast Cancer, Gastric Cancer, and Others), by Distribution Channel (Hospital, Oncology Centers, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Sh

Breast Imaging Market, By Technology (Ionizing Breast Imaging, Non-ionizing Breast Imaging, and Others), By End User (Hospitals, Diagnostic Centers, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Immuno-Oncology Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Cytokines), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End-Users - Global Forecast 2024-2030

Research Assistance

Other tasks